Results 41 to 50 of about 4,918 (159)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review

Obesity Reviews, Volume 27, Issue 8, August 2026.
ABSTRACT Introduction Weight loss results in reduced energy expenditure (EE) due to body composition alterations (e.g., fat‐free mass and fat mass losses) and mass‐independent adaptations in EE (e.g., hormones). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are indicated for obesity management; however, their effects on EE remain unclear ...
Flavio T. Vieira, ZhiDi Deng, Manfred J. Muller, Giovanna G. L. Bergamasco, Sarah Cawsey, Melania Manco, Steven B. Heymsfield, Carla M. Prado, Andrea M. Haqq   +8 more
wiley   +1 more source

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo

International Journal of Nanomedicine, 2019
Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial ...
Lee CH, Hsieh MJ, Chang SH, Hung KC, Wang CJ, Hsu MY, Juang JH, Hsieh IC, Wen MS, Liu SJ   +9 more
doaj  

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, Volume 13, Issue 38, 9 July 2026.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Ten Years of Vildagliptin [PDF]

European Endocrinology, 2017
After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endocrine pancreas and leading to a previously unmet risk ...
openaire   +2 more sources

Hyperglycemic Hyperosmolar Syndrome With Higher Brain Dysfunction in Which Arterial Spin Labeling Revealed Abnormal Cerebral Blood Flow: A Case Report

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Treatment for hyperglycemic hyperosmolar syndrome (HHS) was initiated for a transferred unconscious patient. Aphasia and agnosia remained even after metabolic improvement. Arterial spin labeling (ASL) indicated increased blood flow in the left temporal and parietal lobes.
Go Yoshimichi
wiley   +1 more source

Role of Evogliptin for Intra‐Class Therapeutic Interchange in Patients With Type 2 Diabetes Mellitus: Subgroup Analysis From A Multi‐Center, Prospective, Observational Study (REVISE Study)

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
ICTI to evogliptin from other DPP‐4 inhibitors significantly improved glycemic control in patients with type 2 diabetes inadequately controlled on metformin‐based therapy. The treatment was well tolerated, supporting ICTI as a pragmatic optimization strategy in routine clinical practice. ABSTRACT Aims While dipeptidyl peptidase‐4 (DPP‐4) inhibitors are
Jie‐Eun Lee, Jun Hwa Hong, Sung Hoon Yu, Ki‐Hyun Baek, JaeMyung Yu, Seung Jin Lee, Hyung‐Wook Kim, Kang Seo Park, Jung Han Kim, KyungWan Min, Yong Hwan Lee, Koon Soon Kim, Min Soo Song, Ji Hoon Kim, Jong Chul Won   +14 more
wiley   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5614-5626, July 2026.
ABSTRACT Aims Diabetic retinopathy (DR) is linked to elevated risks of cerebrovascular diseases. Whether sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) reduce stroke risk in patients with type 2 diabetes (T2D) and DR remains uncertain. Materials and Methods We conducted a retrospective cohort study using the TriNetX Research Network.
Kuo‐En Chen, Po‐Chun Wang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source

Valsartan and Amlodipine Improved Haematological and Biochemical Indices of Vildagliptin-treated Streptozotocin-induced Diabetic Rats [PDF]

Pharmaceutical and Biomedical Research
Background: Diabetes mellitus (DM) and hypertension often coexist in sufferers, which exacerbates the complications of DM. Also, the impacts of antihypertensive medications on the treatment outcomes of DM are not fully understood.
Israel Olapeju Bolanl, Osayemwenre Erharuyi, Abigail M. Akhigbemen, Amenaghawon Imuetinyan Ugiagbe, Edobor Ekugum, Samuel O. Nwusulor, Keziah E. Adudu, Abiodun Falodun   +7 more
doaj  

The development of type 2 diabetes amongst sibling pairs in the South‐South region of Nigeria: The effect of genetics, environment and lifestyle

Diabetic Medicine, Volume 43, Issue 6, June 2026.
Abstract Introduction Type 2 diabetes is a complex condition with a multifactorial pathogenesis. The pathogenesis is considered to be polygenic due to complex interactions between genetic/epigenetic and environmental factors. The aim of this study is to determine the genetic, environmental and lifestyle factors associated with the development of type 2
Sunny Chinenye, Ibi Erekosima, Adrian H. Heald, Gesiye Bozimo, Simon G. Anderson, Samuel Seidu, Kariba Akhidue, Adaeze Ugwu, Chioma Unachukwu, Ibitrokoemi Korubo, Kingsley Chukwuemeka Patrick‐Iwuanyanwu, Victoria Gomba, Uwoma Batubo, Victoria Akanatei, Victor Ken‐Uba, Iyeopu Siminialayi, Sokiprim Akoko, Justin Ideozu, Hamilton Opurum   +18 more
wiley   +1 more source

Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress/NF-κB Pathway

Frontiers in Pharmacology, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2 diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on cardiovascular system.
Yuqin Ji, Yingbin Ge, Xinyu Xu, Sen Ye, Yuansheng Fan, Jing Zhang, Lianlian Mei, Xiaofeng Zhang, Lianghong Ying, Tao Yang, Chunjian Li   +10 more
doaj   +1 more source